JP2008530138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530138A5 JP2008530138A5 JP2007555370A JP2007555370A JP2008530138A5 JP 2008530138 A5 JP2008530138 A5 JP 2008530138A5 JP 2007555370 A JP2007555370 A JP 2007555370A JP 2007555370 A JP2007555370 A JP 2007555370A JP 2008530138 A5 JP2008530138 A5 JP 2008530138A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- skin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 3
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000013727 interleukin-31 production Effects 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65311405P | 2005-02-14 | 2005-02-14 | |
| US60/653,114 | 2005-02-14 | ||
| US71676205P | 2005-09-13 | 2005-09-13 | |
| US60/716,762 | 2005-09-13 | ||
| US74995205P | 2005-12-13 | 2005-12-13 | |
| US60/749,952 | 2005-12-13 | ||
| PCT/US2006/005328 WO2006088956A2 (en) | 2005-02-14 | 2006-02-14 | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530138A JP2008530138A (ja) | 2008-08-07 |
| JP2008530138A5 true JP2008530138A5 (enExample) | 2009-04-09 |
| JP4927762B2 JP4927762B2 (ja) | 2012-05-09 |
Family
ID=36685803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555370A Expired - Fee Related JP4927762B2 (ja) | 2005-02-14 | 2006-02-14 | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555369A Pending JP2008530137A (ja) | 2005-02-14 | 2006-02-14 | 皮膚リンパ球抗原陽性細胞により仲介される疾患を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (11) | US20060188499A1 (enExample) |
| EP (2) | EP1856150A2 (enExample) |
| JP (2) | JP4927762B2 (enExample) |
| AU (2) | AU2006214326B2 (enExample) |
| CA (2) | CA2595939C (enExample) |
| IL (3) | IL184734A (enExample) |
| MX (2) | MX2007009471A (enExample) |
| WO (2) | WO2006088955A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP1221482B1 (en) | 1999-09-27 | 2005-12-28 | Chugai Seiyaku Kabushiki Kaisha | Hemopoietin receptor protein, nr12 |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| US10080779B2 (en) | 2004-12-15 | 2018-09-25 | Universite D'angers | Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM |
| ES2579758T3 (es) * | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| CN101198624B (zh) | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| EP2001906A2 (en) | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| ES2544888T3 (es) | 2006-06-08 | 2015-09-04 | Chugai Seiyaku Kabushiki Kaisha | Prevención o remedio para enfermedades inflamatorias |
| EP2061811A2 (en) | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| AU2008204823A1 (en) * | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| CA2708065C (en) | 2007-12-05 | 2015-02-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| SI2796466T1 (en) | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Molecules of Humanized Specifics Specifiable for IL-31 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201537175A (zh) * | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| US10060273B2 (en) | 2015-04-15 | 2018-08-28 | United Technologies Corporation | System and method for manufacture of abrasive coating |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CA3093709C (en) | 2018-03-16 | 2024-03-26 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| JP7449234B2 (ja) | 2018-03-16 | 2024-03-13 | ゾエティス・サービシーズ・エルエルシー | 獣医学使用のためのインターロイキン３１モノクローナル抗体 |
| CN112533675A (zh) * | 2018-04-25 | 2021-03-19 | 基尼克萨制药有限公司 | 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 |
| CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| RU2707181C1 (ru) * | 2019-08-15 | 2019-11-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования степени тяжести течения пруриго методом определения уровня концентрации триптазы в крови |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗ｉｌ３１抗体 |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
| KR102392954B1 (ko) * | 2020-02-11 | 2022-05-02 | 연세대학교 산학협력단 | 아토피 피부염 동물 모델인 아바타마우스의 제조 방법 및 그의 용도 |
| CA3189847A1 (en) | 2020-09-01 | 2022-03-10 | Naoki Fukazawa | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
| EP1426059A4 (en) | 2001-09-14 | 2007-01-17 | Ono Pharmaceutical Co | DRUGS FOR TREATING PRURIT |
| WO2004003140A2 (en) * | 2002-01-18 | 2004-01-08 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| RU2490276C2 (ru) * | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| JP2004219390A (ja) * | 2002-02-22 | 2004-08-05 | Taisho Pharmaceut Co Ltd | アトピー性皮膚炎に対し鎮痒効果を有する薬物の評価方法 |
| WO2003070252A1 (fr) | 2002-02-22 | 2003-08-28 | Taisho Pharmaceutical Co., Ltd. | Agents antiprurigineux |
| JP2004107209A (ja) * | 2002-09-13 | 2004-04-08 | Nippon Oruganon Kk | 掻痒治療薬 |
| JP4503942B2 (ja) * | 2003-06-11 | 2010-07-14 | 大正製薬株式会社 | 止痒剤 |
| EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
| ES2579758T3 (es) | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| JP4927762B2 (ja) | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| CN101198624B (zh) * | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| WO2007037137A1 (ja) * | 2005-09-28 | 2007-04-05 | Konica Minolta Opto, Inc. | 射出成形装置 |
| EP2001906A2 (en) * | 2006-01-10 | 2008-12-17 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| EP2061811A2 (en) * | 2006-09-01 | 2009-05-27 | ZymoGenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| AU2008204823A1 (en) | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc | Methods of using IL-31 to treat airway hyper-responsiveness and asthma |
| SI2796466T1 (en) * | 2007-12-07 | 2018-01-31 | Zymogenetics, Inc. | Molecules of Humanized Specifics Specifiable for IL-31 |
-
2006
- 2006-02-14 JP JP2007555370A patent/JP4927762B2/ja not_active Expired - Fee Related
- 2006-02-14 WO PCT/US2006/005327 patent/WO2006088955A2/en not_active Ceased
- 2006-02-14 US US11/353,427 patent/US20060188499A1/en not_active Abandoned
- 2006-02-14 AU AU2006214326A patent/AU2006214326B2/en not_active Ceased
- 2006-02-14 JP JP2007555369A patent/JP2008530137A/ja active Pending
- 2006-02-14 CA CA2595939A patent/CA2595939C/en not_active Expired - Fee Related
- 2006-02-14 MX MX2007009471A patent/MX2007009471A/es not_active Application Discontinuation
- 2006-02-14 AU AU2006214325A patent/AU2006214325B2/en not_active Ceased
- 2006-02-14 EP EP06735136A patent/EP1856150A2/en not_active Withdrawn
- 2006-02-14 EP EP06735137.9A patent/EP1856539B1/en not_active Expired - Lifetime
- 2006-02-14 CA CA002595877A patent/CA2595877A1/en not_active Abandoned
- 2006-02-14 MX MX2007009577A patent/MX2007009577A/es active IP Right Grant
- 2006-02-14 US US11/353,454 patent/US20060188500A1/en not_active Abandoned
- 2006-02-14 WO PCT/US2006/005328 patent/WO2006088956A2/en not_active Ceased
-
2007
- 2007-07-19 IL IL184734A patent/IL184734A/en not_active IP Right Cessation
- 2007-07-23 IL IL184776A patent/IL184776A/en not_active IP Right Cessation
-
2008
- 2008-09-26 US US12/239,107 patent/US7723048B2/en not_active Expired - Lifetime
-
2009
- 2009-07-02 US US12/497,383 patent/US20090280121A1/en not_active Abandoned
-
2010
- 2010-03-19 US US12/727,912 patent/US8435745B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 US US13/094,482 patent/US8388964B2/en not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219145A patent/IL219145A0/en unknown
-
2013
- 2013-01-30 US US13/754,278 patent/US20130177563A1/en not_active Abandoned
- 2013-03-13 US US13/799,048 patent/US8926957B2/en not_active Expired - Lifetime
-
2015
- 2015-10-09 US US14/879,550 patent/US20160024201A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/384,774 patent/US20170096484A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,883 patent/US20190040125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9068988B2 (en) | Compositions and methods of detecting TIABs | |
| JP2008530137A5 (enExample) | ||
| KR20200106053A (ko) | Atr 억제제를 사용한 암 치료 방법 | |
| MY162024A (en) | Antagonistic human light-specific human monoclonal antibodies | |
| NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
| BR112012008665A2 (pt) | tratamento de câncer | |
| NZ611117A (en) | Anti mif antibodies | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2015525230A5 (enExample) | ||
| SG178567A1 (en) | Affinity-matured humanized anti cea monoclonal antibodies | |
| WO2006088956A3 (en) | Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists | |
| Harvey et al. | Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus | |
| CN116970081B (zh) | 一种抗人源cd132的单克隆抗体及其应用 | |
| JP2016523910A5 (enExample) | ||
| ATE502305T1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| NZ591918A (en) | Antibodies to modified human igf-1/e peptides | |
| WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
| JP2013500739A5 (enExample) | ||
| Takazawa et al. | Endoplasmic reticulum stress transducer old astrocyte specifically induced substance contributes to astrogliosis after spinal cord injury | |
| EP1778284A4 (en) | NUCLEIC ACIDS AND RELATED 58P1D12 PROTEINS FOR THE TREATMENT AND DETECTION OF CANCER | |
| JP2008516985A5 (enExample) | ||
| JP2019531254A5 (enExample) | ||
| CN120843525B (zh) | 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用 | |
| EP3270950A1 (en) | Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases | |
| CN104447991A (zh) | 白细胞介素-31多克隆或单克隆抗体的制备方法及应用 |